AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Zymeworks to Present at Stifel 2019 Healthcare Conference

November 4, 2019

VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov 4, 2019--

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present at the upcoming Stifel 2019 Healthcare Conference taking place November 19-20, 2019 in New York, NY.

The Company’s presentation will be on Tuesday, November 19, 2019 at 8:00 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005136/en/

CONTACT: Zymeworks Inc.Investor Inquiries: 

Ryan Dercho, Ph.D. 

(604) 678-1388 

ir@zymeworks.com Tiffany Tolmie 

(604) 678-1388 

ir@zymeworks.com Media Inquiries: 

Kavita Shah, Ph.D.

(604) 678-1388 

info@zymeworks.com 

KEYWORD: UNITED STATES NORTH AMERICA CANADA NEW YORK

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: Zymeworks Inc.

Copyright Business Wire 2019.

PUB: 11/04/2019 04:15 PM/DISC: 11/04/2019 04:15 PM

http://www.businesswire.com/news/home/20191104005136/en